These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21751539)

  • 1. [The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial)].
    Krupicka J; Soucek M; Chroust K
    Vnitr Lek; 2011 Jun; 57(6):541-5. PubMed ID: 21751539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxonidine: a review of its use in essential hypertension.
    Fenton C; Keating GM; Lyseng-Williamson KA
    Drugs; 2006; 66(4):477-96. PubMed ID: 16597164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of moxonidine in elderly patients with resistant hypertension.
    Martin U; Hill C; O' Mahony D
    J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare psychotropic adverse event of moxonidine.
    Fuckar K; Lakusić N; Cerovec D
    Psychiatr Danub; 2009 Dec; 21(4):518. PubMed ID: 19935487
    [No Abstract]   [Full Text] [Related]  

  • 8. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenetic role of moxonidine in the treatment of hypertension in postmenopausal women].
    Podzolkov VI; Bragina AE; Makolkin VI
    Kardiologiia; 2002; 42(11):32-5. PubMed ID: 12494033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term experiences with moxonidine, a new antihypertensive agent].
    Schwarz W; Kandziora J
    Fortschr Med; 1990 Nov; 108(32):616-20. PubMed ID: 2262193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
    Masajtis-Zagajewska A; Majer J; Nowicki M
    Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
    Abellán J; Leal M; Hernández-Menárguez F; García-Galbis JA; Martínez-Pastor A; de Vinuesa SG; Luño J
    Kidney Int Suppl; 2005 Jan; (93):S20-4. PubMed ID: 15613062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of moxonidine on endothelial dysfunction in metabolic syndrome.
    Topal E; Cikim AS; Cikim K; Temel I; Ozdemir R
    Am J Cardiovasc Drugs; 2006; 6(5):343-8. PubMed ID: 17083269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
    Lazebnik LB; Malichenko SB; Serebrov AN
    Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
    Zaslavskaia RM; Komarov FI; Shakirova AN; Teĭblium MM; Akhmetov KZh
    Klin Med (Mosk); 2000; 78(4):41-4. PubMed ID: 10833890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.